# New Group Launches Ahead of Medicare CBD Pilots > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/medicare-cbd-pilot-programs-launch/ > **Published:** 2026-03-15T22:56:13-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:09:16-04:00 > **Clinical Summary:** Explore Medicare CBD pilot programs shaping clinical evidence and coverage for cannabis-derived therapeutics in older adults. --- ✦ New CED Clinical Relevance #95 Landmark Clinical Evidence Peer-reviewed human research with direct implications for [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practice. PolicyResearchCBDAging Clinical Summary Medicare’s launch of cannabidiol (CBD) pilot programs represents a significant shift in federal recognition of [cannabis-derived therapeutics](https://cedclinic.com/cannabis-related-regulatory-documents-dea/), with new stakeholder groups forming to shape implementation and evidence standards. These pilots will generate data on CBD’s clinical efficacy and safety in Medicare beneficiaries, potentially informing future coverage decisions that could affect millions of older adults. The formation of coalitions around these initiatives suggests active engagement from industry, advocacy, and medical stakeholders seeking to influence pilot design, patient selection criteria, and outcome measures. For clinicians, successful pilots could establish reimbursement pathways for CBD in specific indications, while also setting precedent for how cannabis products are evaluated within mainstream healthcare systems. The outcomes of these programs will likely determine whether other cannabis-derived medications gain similar Medicare consideration, fundamentally altering access and coverage for patients. Clinicians should monitor pilot results and emerging evidence from these programs, as favorable data could expand treatment options for their patients, particularly older adults with chronic conditions currently managing multiple pharmaceuticals. Dr. Caplan’s Take “We’re finally seeing the institutional infrastructure develop to answer the questions our patients have been asking for two decades, and that’s meaningful, but Medicare pilots will only matter if we train clinicians to actually use the data responsibly—right now most physicians still can’t distinguish between a legitimate CBD product and snake oil on a shelf.” Clinical Perspective The emergence of advocacy groups and industry partnerships positioning themselves ahead of Medicare’s CBD pilot programs reflects growing interest in [cannabinoid therapeutics](https://cedclinic.com/medcan3-trial-cancer-symptoms/) within formal healthcare systems, though clinicians should recognize that pilot participation does not equate to established safety or efficacy. Current evidence for CBD remains limited to specific indications like seizure disorders, with robust data lacking for most conditions patients or advocates may expect it to treat, and the heterogeneity of [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/), dosing standards, and manufacturing quality create significant challenges for clinical implementation. Healthcare providers participating in or advising patients about these pilots should maintain healthy skepticism regarding promotional claims while carefully documenting patient outcomes, understanding that these programs may eventually inform regulatory pathways but currently operate in a landscape of incomplete evidence. The involvement of organized groups in shaping pilot structure highlights the importance of clinician input in ensuring that study designs prioritize rigorous outcome measurement and patient safety over market expansion. Practically, providers should counsel patients interested in CBD 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+New+Group+Launches+Ahead+of+Medicare+CBD+Pilots+-+%3Cb%3ECannabis%3C%2Fb%3E+Wire+%40drcaplan&url=https%3A%2F%2Fcannabiswire.com%2Fnewsletters%2Fnew-group-launches-ahead-of-medicare-cbd-pilots%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcannabiswire.com%2Fnewsletters%2Fnew-group-launches-ahead-of-medicare-cbd-pilots%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+New+Group+Launches+Ahead+of+Medicare+CBD+Pilots+-+%3Cb%3ECannabis%3C%2Fb%3E+Wire+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fcannabiswire.com%2Fnewsletters%2Fnew-group-launches-ahead-of-medicare-cbd-pilots%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [CED Digest: 230 Items — March 15, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-clinical-relevance-2026/) - [CED Digest: 436 Items — March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 405 Items — March 12, 2026](https://cedclinic.com/alabama-medical-cannabis-sales-2026-spring-launch/) 📰 Source: [https://cannabiswire.com/newsletters/new-group-launches-ahead-of-medicare-cbd-pilots/](https://cannabiswire.com/newsletters/new-group-launches-ahead-of-medicare-cbd-pilots/) Further Reading Evidence WatchIGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial Research Digest[AM Policy Update: March 15, 2026](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Federal Judge to Decide Whether Medicare Can Distribute Hemp-Marijuana Cannabinoids …](https://cedclinic.com/medicare-cannabinoid-reimbursement-federal-judge-review/) Legal perspectives on Medicare's ability to distribute hemp-marijuana cannabinoids and implications for [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/). [Read More](https://cedclinic.com/medicare-cannabinoid-reimbursement-federal-judge-review/) [U.S. Launches Medicare's Pilot Hemp Program – Shanken News Daily](https://cedclinic.com/medicare-hemp-therapeutic-pilot-program/) Details on the launch of Medicare's pilot hemp program and its significance for cannabinoid therapeutics. [Explore Article](https://cedclinic.com/medicare-hemp-therapeutic-pilot-program/) [High Tide Subsidiary NuLeaf Naturals Pursues Participation in U.S. Medicare CBD Pilot …](https://cedclinic.com/medicare-cbd-insurance-coverage-policy-pilot/) Industry involvement in Medicare CBD pilots highlighting the evolving landscape of cannabis medicine. [Learn More](https://cedclinic.com/medicare-cbd-insurance-coverage-policy-pilot/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).